Safety, Tolerability, and Pharmacodynamics of ABT ‐122, a TNF‐ and IL‐17–Targeted Dual Variable Domain Immunoglobulin, in Patients With RA

ConclusionThese phase 1 results suggest that dual neutralization with ABT‐122 has a profile acceptable for further exploration of therapeutic potential in TNF‐ and IL‐17A–driven immune‐mediated inflammatory diseases.This article is protected by copyright. All rights reserved.

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fart.40319

Source: Arthritis and Rheumatism - September 21, 2017 Category: Rheumatology Authors: Roy M. Fleischmann, Frank Wagner, Alan J. Kivitz, Heikki T. Mansikka, Nasser Khan, Ahmed A. Othman, Amit Khatri, Feng Hong, Ping Jiang, Melanie Ruzek, Robert J. Padley Tags: Full Length Source Type: research